Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of C Difficile Infection Drug market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of C Difficile Infection Drugmarket, defines the market attractiveness level of C Difficile Infection Drug market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of C Difficile Infection Drug industry, describes the types of C Difficile Infection Drug market, the applications of major players and the market size, and deeply analyzes the current situation of the global C Difficile Infection Drug market and the development prospects and opportunities of C Difficile Infection Drug industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global C Difficile Infection Drug market in Chapter 13.
By Player:
AstraZeneca
Flynn Pharma
ANI Pharmaceutical
Strides
Xellia
Lupin
Aspen Pharmacare
Akorn
Pfizer
Zhejiang Medicine
Merus labs
Eli Lilly
Merck
Astellas
Sanofi
Fresenius
By Type:
Metronidazole
Vancomycin
Fidaxomycin
Others
By End-User:
Pre-treatment
Mid-term treatment
Others
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 C Difficile Infection Drug Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 C Difficile Infection Drug Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 C Difficile Infection Drug Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 C Difficile Infection Drug Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise C Difficile Infection Drug Market Analysis and Outlook to 2022
-
7.1 Global C Difficile Infection Drug Consumption (2017-2022)
-
7.2 United States C Difficile Infection Drug Consumption (2017-2022)
-
7.3 Europe C Difficile Infection Drug Consumption (2017-2022)
-
7.4 China C Difficile Infection Drug Consumption (2017-2022)
-
7.5 Japan C Difficile Infection Drug Consumption (2017-2022)
-
7.6 India C Difficile Infection Drug Consumption (2017-2022)
-
7.7 South Korea C Difficile Infection Drug Consumption (2017-2022)
8 Region and Country-wise C Difficile Infection Drug Market Analysis and Outlook to 2028
-
8.1 Global C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.2 United States C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.3 Europe C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.4 China C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.5 Japan C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.6 India C Difficile Infection Drug Consumption Forecast (2022-2028)
-
8.7 South Korea C Difficile Infection Drug Consumption Forecast (2022-2028)
9 Global C Difficile Infection Drug Market Outlook by Types and Applications to 2022
-
9.1 Global C Difficile Infection Drug Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Metronidazole Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Vancomycin Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Fidaxomycin Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global C Difficile Infection Drug Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Pre-treatment Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Mid-term treatment Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Others Consumption and Growth Rate (2017-2022)
10 Global C Difficile Infection Drug Market Outlook by Types and Applications to 2028
-
10.1 Global C Difficile Infection Drug Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Metronidazole Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Vancomycin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Fidaxomycin Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global C Difficile Infection Drug Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Pre-treatment Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Mid-term treatment Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)
11 Global C Difficile Infection Drug Import and Export Analysis (Top 5 Countries)
-
11.1 Global C Difficile Infection Drug Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global C Difficile Infection Drug Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 C Difficile Infection Drug Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global C Difficile Infection Drug Market Competitive Analysis
-
14.1 AstraZeneca
-
14.1.1 AstraZeneca Company Details
-
14.1.2 AstraZeneca C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 AstraZeneca C Difficile Infection Drug Product and Service
-
14.2 Flynn Pharma
-
14.2.1 Flynn Pharma Company Details
-
14.2.2 Flynn Pharma C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Flynn Pharma C Difficile Infection Drug Product and Service
-
14.3 ANI Pharmaceutical
-
14.3.1 ANI Pharmaceutical Company Details
-
14.3.2 ANI Pharmaceutical C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 ANI Pharmaceutical C Difficile Infection Drug Product and Service
-
14.4 Strides
-
14.4.1 Strides Company Details
-
14.4.2 Strides C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Strides C Difficile Infection Drug Product and Service
-
14.5 Xellia
-
14.5.1 Xellia Company Details
-
14.5.2 Xellia C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Xellia C Difficile Infection Drug Product and Service
-
14.6 Lupin
-
14.6.1 Lupin Company Details
-
14.6.2 Lupin C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 Lupin C Difficile Infection Drug Product and Service
-
14.7 Aspen Pharmacare
-
14.7.1 Aspen Pharmacare Company Details
-
14.7.2 Aspen Pharmacare C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Aspen Pharmacare C Difficile Infection Drug Product and Service
-
14.8 Akorn
-
14.8.1 Akorn Company Details
-
14.8.2 Akorn C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Akorn C Difficile Infection Drug Product and Service
-
14.9 Pfizer
-
14.9.1 Pfizer Company Details
-
14.9.2 Pfizer C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Pfizer C Difficile Infection Drug Product and Service
-
14.10 Zhejiang Medicine
-
14.10.1 Zhejiang Medicine Company Details
-
14.10.2 Zhejiang Medicine C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Zhejiang Medicine C Difficile Infection Drug Product and Service
-
14.11 Merus labs
-
14.11.1 Merus labs Company Details
-
14.11.2 Merus labs C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Merus labs C Difficile Infection Drug Product and Service
-
14.12 Eli Lilly
-
14.12.1 Eli Lilly Company Details
-
14.12.2 Eli Lilly C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Eli Lilly C Difficile Infection Drug Product and Service
-
14.13 Merck
-
14.13.1 Merck Company Details
-
14.13.2 Merck C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Merck C Difficile Infection Drug Product and Service
-
14.14 Astellas
-
14.14.1 Astellas Company Details
-
14.14.2 Astellas C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Astellas C Difficile Infection Drug Product and Service
-
14.15 Sanofi
-
14.15.1 Sanofi Company Details
-
14.15.2 Sanofi C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.15.3 Sanofi C Difficile Infection Drug Product and Service
-
14.16 Fresenius
-
14.16.1 Fresenius Company Details
-
14.16.2 Fresenius C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
14.16.3 Fresenius C Difficile Infection Drug Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of C Difficile Infection Drug
-
Figure C Difficile Infection Drug Picture
-
Table Global C Difficile Infection Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global C Difficile Infection Drug Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global C Difficile Infection Drug Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global C Difficile Infection Drug Consumption by Country (2017-2022)
-
Figure United States C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Table Europe C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Figure China C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Figure Japan C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Figure India C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Figure South Korea C Difficile Infection Drug Consumption and Growth Rate (2017-2022)
-
Figure Global C Difficile Infection Drug Consumption Forecast by Country (2022-2028)
-
Figure United States C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure China C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure India C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea C Difficile Infection Drug Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Metronidazole Consumption and Growth Rate (2017-2022)
-
Figure Global Vancomycin Consumption and Growth Rate (2017-2022)
-
Figure Global Fidaxomycin Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Pre-treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Mid-term treatment Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Metronidazole Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Vancomycin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Fidaxomycin Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Pre-treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Mid-term treatment Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Table Global C Difficile Infection Drug Import by Region (Top 5 Countries) (2017-2028)
-
Table Global C Difficile Infection Drug Export by Region (Top 5 Countries) (2017-2028)
-
Table AstraZeneca (Foundation Year, Company Profile and etc.)
-
Table AstraZeneca C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table AstraZeneca C Difficile Infection Drug Product and Service
-
Table Flynn Pharma (Foundation Year, Company Profile and etc.)
-
Table Flynn Pharma C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Flynn Pharma C Difficile Infection Drug Product and Service
-
Table ANI Pharmaceutical (Foundation Year, Company Profile and etc.)
-
Table ANI Pharmaceutical C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table ANI Pharmaceutical C Difficile Infection Drug Product and Service
-
Table Strides (Foundation Year, Company Profile and etc.)
-
Table Strides C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Strides C Difficile Infection Drug Product and Service
-
Table Xellia (Foundation Year, Company Profile and etc.)
-
Table Xellia C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Xellia C Difficile Infection Drug Product and Service
-
Table Lupin (Foundation Year, Company Profile and etc.)
-
Table Lupin C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Lupin C Difficile Infection Drug Product and Service
-
Table Aspen Pharmacare (Foundation Year, Company Profile and etc.)
-
Table Aspen Pharmacare C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Aspen Pharmacare C Difficile Infection Drug Product and Service
-
Table Akorn (Foundation Year, Company Profile and etc.)
-
Table Akorn C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Akorn C Difficile Infection Drug Product and Service
-
Table Pfizer (Foundation Year, Company Profile and etc.)
-
Table Pfizer C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer C Difficile Infection Drug Product and Service
-
Table Zhejiang Medicine (Foundation Year, Company Profile and etc.)
-
Table Zhejiang Medicine C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Zhejiang Medicine C Difficile Infection Drug Product and Service
-
Table Merus labs (Foundation Year, Company Profile and etc.)
-
Table Merus labs C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merus labs C Difficile Infection Drug Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly C Difficile Infection Drug Product and Service
-
Table Merck (Foundation Year, Company Profile and etc.)
-
Table Merck C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck C Difficile Infection Drug Product and Service
-
Table Astellas (Foundation Year, Company Profile and etc.)
-
Table Astellas C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas C Difficile Infection Drug Product and Service
-
Table Sanofi (Foundation Year, Company Profile and etc.)
-
Table Sanofi C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi C Difficile Infection Drug Product and Service
-
Table Fresenius (Foundation Year, Company Profile and etc.)
-
Table Fresenius C Difficile Infection Drug Sales, Price, Value and Gross Profit (2017-2022)
-
Table Fresenius C Difficile Infection Drug Product and Service
-
